Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx
We have temporarily suspended our nanoparticle operations. Please revisit us in the future. We apologize for the inconvenience. Any questions, please email: info@imagionbio.com Dismiss